 The stock price of Forward Pharma AS NASDAQ: FWP fell by almost 20 during the premarket. Investors are responding negatively to the Technical Board of Appeal TBA of the European Patent Office EPO, dismissing Forwards appeal to revoke the EP2801355 patent 355 patent following the oral hearing. 